Resveratrol in multiple sclerosis

The requested reference [87702c0c442157f91752a2d2aea18f51de4da4aa] no longer exists in our database. It has been replaced by the current reference: [9e495dab46c7013708c88b2723ea1098ed48fb74]

Authors
Category Primary study
Registry of TrialsIranian Registry of Clinical Trials
Year 2023
INTERVENTION: Intervention 1: Intervention group: 500 mg of resveratrol (in the form of two capsules made by Raha Company) for 8 weeks. Intervention 2: Control group: tow placebo per day (made by Raha company) for 8 weeks. CONDITION: Multiple Sclerosis. ; Multiple sclerosis PRIMARY OUTCOME: Fatigue scale. Timepoint: Before and two months after intervention. Method of measurement: MFIS questionnaire. MDA. Timepoint: Before and two months after intervention. Method of measurement: ELISA. Tumor Necrosis Factor Alpha (TNF‐a). Timepoint: Before and two months after intervention. Method of measurement: ELISA. SECONDARY OUTCOME: Fasting Blood Sugar. Timepoint: Before and two months after intervention. Method of measurement: Enzymatic. Lipid Profile (TC , TG, HDL, LDL). Timepoint: Before and two months after intervention. Method of measurement: Enzymatic. INCLUSION CRITERIA: The disease is diagnosed according to McDonald's criteria. EDSS score 0 to 5 The clinical condition of the patient is relapse‐remittance. Age 18 to 65 years
Epistemonikos ID: 5d2be76dc0c387ed866a4d212d614ec2aeca281d
First added on: Feb 20, 2024